On November 8, 2019 Omeros Corporation (Nasdaq: OMER) reported an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances T-cell responses" at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Tumor Immunology and Immunotherapy, which is being held November 17 – 20, 2019 in Boston, Massachusetts (Press release, Omeros, NOV 8, 2019, View Source [SID1234550804]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Marc Gavin, Ph.D., Omeros’ Director of Immunology, will present the company’s new findings that phosphatidylserine, a product of cell stress and death that is abundant in the tumor microenvironment (TME), directly stimulates GPR174 and attenuates T-cell responses.
Adenosine, another product of the TME, is well known to stimulate the same suppressive pathways through different GPCRs, and inhibition of both pathways—with adenosine receptor antagonists and with Omeros’ novel GPR174 inhibitors—results in maximal enhancement of T-cell function, which should translate to effective resistance to the immunosuppressive nature of the TME.
The data will also feature new findings from animal tumor models, which validate GPR174 inhibition for cancer immunotherapy.
Designated B45, the poster will be presented in Poster Session B on Tuesday, November 19, 4:30 p.m. to 7:00 p.m.